About Tevogen Bio Holdings Inc.
https://tevogen.comTevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID.
CEO
Ryan H. Saadi M.P.H,
Compensation Summary
(Year 2024)
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
FOURWORLD CAPITAL MANAGEMENT LLC
Shares:1.45M
Value:$57.27K
CORBIN CAPITAL PARTNERS, L.P.
Shares:1.16M
Value:$45.82K
HIGHBRIDGE CAPITAL MANAGEMENT LLC
Shares:1.15M
Value:$45.49K
Summary
Showing Top 3 of 40
About Tevogen Bio Holdings Inc.
https://tevogen.comTevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $5.7M ▲ | $-5.73M ▼ | 0% | $-0.03 ▲ | $-5.64M ▼ |
| Q2-2025 | $0 | $5.15M ▼ | $-5.5M ▲ | 0% | $-0.03 ▲ | $-5.18M ▲ |
| Q1-2025 | $0 | $10.25M ▲ | $-10.37M ▼ | 0% | $-0.07 ▼ | $-10.24M ▼ |
| Q4-2024 | $0 | $9.26M ▲ | $-9.25M ▼ | 0% | $-0.05 ▼ | $-9.33M ▼ |
| Q3-2024 | $0 | $5.98M | $-5.91M | 0% | $-0.03 | $-5.77M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.04M ▲ | $4.49M ▲ | $12.32M ▼ | $-7.82M ▲ |
| Q2-2025 | $685.23K ▼ | $4.27M ▲ | $13.75M ▲ | $-9.48M ▼ |
| Q1-2025 | $1.97M ▲ | $4.07M ▲ | $11.79M ▲ | $-7.72M ▼ |
| Q4-2024 | $1.28M ▼ | $3.46M ▼ | $10.14M ▼ | $-6.67M ▼ |
| Q3-2024 | $2.33M | $4.29M | $10.48M | $-6.19M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-5.73M ▼ | $-3.65M ▼ | $0 | $4M ▲ | $351.87K ▲ | $-3.65M ▼ |
| Q2-2025 | $-5.5M ▲ | $-3.19M ▲ | $0 | $1.9M ▼ | $-1.29M ▼ | $-3.19M ▲ |
| Q1-2025 | $-10.37M ▼ | $-3.31M ▼ | $0 | $4M ▲ | $691.94K ▲ | $-3.31M ▼ |
| Q4-2024 | $-9.25M ▼ | $-3.05M ▲ | $0 | $2M ▼ | $-1.05M ▼ | $-3.05M ▲ |
| Q3-2024 | $-5.88M | $-3.8M | $0 | $5M | $1.2M | $-3.8M |
CEO
Ryan H. Saadi M.P.H,
Compensation Summary
(Year 2024)
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
FOURWORLD CAPITAL MANAGEMENT LLC
Shares:1.45M
Value:$57.27K
CORBIN CAPITAL PARTNERS, L.P.
Shares:1.16M
Value:$45.82K
HIGHBRIDGE CAPITAL MANAGEMENT LLC
Shares:1.15M
Value:$45.49K
Summary
Showing Top 3 of 40